Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with recognized
variability in clinical outcome, genetic features, and cells of origin. To date, transcriptional …

Identification of large B-cell lymphomas that are “extra-aggressive” and may require therapy
other than that used for diffuse large B-cell lymphoma, not otherwise specified (DLBCL …

Germinal center (GC) and non-GC phenotypes are predictors of outcome in diffuse large B-
cell lymphoma (DLBCL) and can be used to stratify chemotherapy-treated patients into low …

Abstract The t (14; 18) is present in a significant proportion of diffuse large B-cell lymphomas
(DLBCLs), however, the prognostic effect of the translocation and the relationship with …

Background The introduction of rituximab (R) to conventional CHOP chemotherapy for newly
diagnosed diffuse large B-cell lymphoma (DLBCL) led to an unequivocal improvement in …

To gain insight into the genomic basis of diffuse large B-cell lymphoma (DLBCL), we
performed massively parallel whole-exome sequencing of 55 primary tumor samples from …

B-cell non-Hodgkin lymphoma (B-NHL) encompasses multiple clinically and phenotypically
distinct subtypes of malignancy with unique molecular etiologies. Common subtypes of B …

B cell diffuse large cell lymphoma (B-DLCL) is a heterogeneous group of tumors, based on
significant variations in morphology, clinical presentation, and response to treatment. Gene …

Diffuse large B cell lymphoma (DLBCL) is a clinically and genetically heterogeneous
disease. A small subset of DLBCLs has translocations involving the MYC locus and an …

Purpose: Relapsed or refractory diffuse large B-cell lymphoma (rrDLBCL) is fatal in 90% of
patients, and yet little is known about its biology. Experimental Design: Using exome …